

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

2026 FIRST QUARTERLY REPORT

This announcement is made by Pharmaron Beijing Co., Ltd. (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The following is the first quarterly report for 2026 of the Company. The financial data contained in this quarterly report is, except for Part (IV) in section IV which has been prepared in accordance with the International Financial Reporting Standards issued by the International Accounting Standard Board (the “**IFRSs**”) or as otherwise indicated, prepared in accordance with the PRC Accounting Standards for Business Enterprises. The first quarterly report for 2026 of the Company has not been audited.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. LOU Boliang
Chairman

Beijing, the PRC
April 28, 2026

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Li Shing Chung Gilbert as employee representative Director, Mr. Li Jiaqing and Ms. Wan Xuan as non-executive Directors; Ms. Li Lihua, Prof. Tsang King Fung and Mr. Yu Jian as independent non-executive Directors.

Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司

**6 Tai-He Road, Beijing Economic Technological
Development Area, Beijing, China**

2026 FIRST QUARTERLY REPORT

April 2026

IMPORTANT NOTICE:

- 1. The Board of Directors and the Directors, and senior management warrant the truthfulness, accuracy and completeness of the Quarterly Report and that there are no false information, misleading statements or material omissions in the Quarterly Report, and shall assume joint and several legal responsibility.**
- 2. The person in charge of the Company, the Chief Financial Officer and the person in charge of Accounting Department (accounting head) of the Company warrant the truthfulness, accuracy and completeness of the financial information contained in the Quarterly Report.**
- 3. Whether the First Quarterly Report has been audited**

Yes No

I. MAJOR FINANCIAL DATA

(I) Major accounting data and financial indicators

Any necessary retrospective adjustment or restatement of the accounting data of the previous years

Yes No

| | The reporting period | The corresponding period of the previous year | Increase/ (decrease) of the reporting period as compared with the corresponding period of the previous year |
|--|--|---|---|
| Revenue (<i>RMB</i>) | 3,578,424,402.86 | 3,098,813,569.89 | 15.48% |
| Net profit attributable to owners of the parent (<i>RMB</i>) | 335,359,234.94 | 305,575,186.04 | 9.75% |
| Net profit attributable to owners of the parent excluding non-recurring gains or losses (<i>RMB</i>) | 343,439,584.32 | 292,410,967.83 | 17.45% |
| Non-IFRS adjusted net profit attributable to owners of the parent (<i>RMB</i>) | 406,210,066.18 | 349,441,031.17 | 16.25% |
| Net cash flow from operating activities (<i>RMB</i>) | 604,439,916.55 | 852,829,144.27 | -29.13% |
| Basic earnings per share (<i>RMB/share</i>) | 0.1860 | 0.1736 | 7.14% |
| Diluted earnings per share (<i>RMB/share</i>) | 0.1850 | 0.1733 | 6.75% |
| Return on net assets on weighted average basis | 2.10% | 2.21% | decreased 0.11 percentage points |
| | | | Increase/(decrease) at the end of the reporting period as compared with the end of the previous year |
| | As at the end of the reporting period | As at the end of the previous year | |
| Total assets (<i>RMB</i>) | 28,561,705,821.71 | 27,093,782,579.04 | 5.42% |
| Net assets attributable to owners of the parent (<i>RMB</i>) | 16,458,476,083.78 | 15,064,159,256.08 | 9.26% |

Revenue, cost and gross profit margin by products or services for the first quarter of 2026 as well as their period-on-period changes are as follows:

Unit: RMB

| By products or services | The reporting period | | | The corresponding period of the previous year | | | Increase/ (decrease) in revenue as compared with the corresponding period of the previous year |
|------------------------------------|----------------------|------------------|---------------------|---|------------------|---------------------|--|
| | Revenue | Cost | Gross profit margin | Revenue | Cost | Gross profit margin | |
| Laboratory services | 2,122,238,672.13 | 1,186,149,632.13 | 44.11% | 1,857,202,616.77 | 1,011,417,257.37 | 45.54% | 14.27% |
| CMC (small molecule CDMO) services | 866,365,472.53 | 593,899,482.95 | 31.45% | 693,023,486.59 | 482,048,054.08 | 30.44% | 25.01% |
| Clinical development services | 500,106,687.28 | 464,601,909.11 | 7.10% | 447,320,929.08 | 394,707,942.00 | 11.76% | 11.80% |
| Biologics and CGT services | 87,833,395.62 | 169,338,830.54 | -92.80% | 98,693,179.32 | 166,659,328.60 | -68.87% | -11.00% |

For the first quarter of 2026, the Company's laboratories and manufacturing facilities in China, which serve the global customers, recorded a period-on-period revenue growth of 17.59%, accounting for 89.35% of the revenue; the Company's laboratories and manufacturing facilities overseas recorded a period-on-period revenue increase of 0.34%, accounting for 10.65% of the revenue of the Company.

By customer types, for the first quarter of 2026, the Company's revenue from the global top 20 pharmaceutical companies was RMB674,413,000, with an increase of 47.98% on a period-on-period basis, accounting for 18.85% of the revenue of the Company; the revenue from other customers was RMB2,904,011,400, with an increase of 9.87% on a period-on-period basis, accounting for 81.15% of the revenue of the company, of which, new customers contributed revenue accounting for 1.53% of the revenue.

By regions of which the customers are located, for the first quarter of 2026, the revenue from customers in North America was RMB2,195,852,200, with an increase of 9.61% on a period-on-period basis, accounting for 61.37% of the revenue of the Company; the revenue from customers in EU (including the U.K.) was RMB629,463,500, with an increase of 10.66% on a period-on-period basis, accounting for 17.59% of the revenue of the Company; the revenue from customers in China was RMB655,250,000, with an increase of 43.41% on a period-on-period basis, accounting for 18.31% of the revenue of the Company; and the revenue from customers in other regions was RMB97,858,700, accounting for 2.73% of revenue of the Company.

In the first quarter of 2026, the Company's newly signed purchase orders increased by more than 30% period-on-period, driven by more than 20% growth in laboratory services and more than 50% growth in CMC (small molecule CDMO) services.

(II) Non-recurring gains or losses items and amounts

Applicable Not Applicable

Unit: RMB

| Item | The reporting period | Note |
|---|----------------------|--|
| Gains or losses from disposal of non-current assets (including written-off portion of provisions for assets impairment) | 1,122,671.30 | |
| Government grants included in profit/(loss) of the current period (except for those closely related to the Company's ordinary business and granted on an ongoing basis under the state's policies according to certain standard amount or volume) | 22,707,204.16 | It was mainly due to government subsidies related to daily activities. |
| Gains or losses on changes in fair value of arising from financial assets, financial liabilities held by non-financial company, and investment income from disposal of financial assets, financial liabilities held by non-financial company, except effective hedging activities related to the Company's normal business operations | -1,614,724.43 | |
| Other non-operating income and expenses other than the above items | -5,758,332.47 | |
| Less: Effect of income tax | 28,539,133.74 | |
| Impact on non-controlling interests (after tax) | -4,001,965.80 | |
| Total | <u>-8,080,349.38</u> | |

Other specific circumstances of gains or losses items that meet the definition of non-recurring gains or losses:

Applicable Not Applicable

The Company did not have other specific circumstances of gains or losses items that meet the definition of non-recurring gains or losses.

Description of non-recurring gains or losses items as illustrated in the Explanatory Announcement No. 1 for Information Disclosure by Public Issuers of Securities – Non-recurring Gains or Losses Items defined as recurring gains or losses items:

Applicable Not Applicable

The Company did not list any non-recurring gains or losses items as illustrated in the Explanatory Announcement No. 1 for Information Disclosure by Public Issuers of Securities – Non-recurring Gains or Losses Items as recurring gain or loss items.

(III) Changes in major accounting data and financial indicators and the reasons thereof

✓ Applicable □ Not Applicable

| Item | As at the end of the reporting period/amount of the current period (RMB) | Balance at the beginning of the year/the corresponding period of the previous year (RMB) | Percentage of changes | Reasons for changes |
|----------------------------------|---|---|-----------------------|--|
| Cash and bank balances | 2,378,989,128.19 | 1,017,482,059.69 | 133.81% | Cash and bank balances increased by RMB1,361,507,100 on a period-on-period basis during the reporting period, representing an increase of 133.81%, including: cash and cash equivalents increased by RMB1,444,444,000. Please refer to the consolidated statement of cash flows for details. |
| Derivative financial assets | 1,547,675.85 | 22,549,918.77 | -93.14% | Derivative financial assets decreased by RMB21,002,200 as compared with the balance at the beginning of the year, representing a decrease of 93.14%, it was due to changes in the fair value of derivative financial instruments. |
| Prepayments | 101,933,567.76 | 18,917,151.23 | 438.84% | Prepayments increased by RMB83,016,400 as compared with the balance at the beginning of the year, representing an increase of 438.84%, mainly due to the increase in prepayments for inventories purchases. |
| Derivative financial liabilities | 5,643,596.52 | | N/A | It was due to changes in the fair value. |
| Other comprehensive income | -56,096,680.68 | 71,798,265.22 | -178.13% | Other comprehensive income decreased by RMB127,894,900 as compared with the balance at the beginning of the year, representing a decrease of 178.13%, mainly due to the decrease in change in the exchange differences on translation of foreign financial statements. |

| Item | As at the end of the reporting period/amount of the current period (RMB) | Balance at the beginning of the year/the corresponding period of the previous year (RMB) | Percentage of changes | Reasons for changes |
|-------------------------------|---|---|-----------------------|---|
| Finance expenses | 86,733,968.38 | 46,577,702.67 | 86.21% | Finance expenses increased by RMB40,156,300 on a period-on-period basis during the reporting period, representing an increase of 86.21%, mainly due to the period-on-period increase in losses from foreign exchange. |
| Other income | 22,699,704.16 | 13,846,641.70 | 63.94% | Other income increased by RMB8,853,100 on a period-on-period basis during the reporting period, representing an increase of 63.94%, it was due to the period-on-period increase in government subsidies related to daily activities. |
| Investment income | 21,246,202.92 | -14,632,689.59 | 245.20% | Investment income increased by RMB35,878,900 on a period-on-period basis during the reporting period, representing an increase of 245.20%, mainly due to the period-on-period increase in investment income from associates. |
| Gains on change in fair value | -8,181,579.08 | -12,799,396.87 | 36.08% | Gains on change in fair value increased by RMB4,617,800 on a period-on-period basis during the reporting period, representing an increase of 36.08%, mainly due to the decrease in losses on change in fair value of biological assets. |
| Assets impairment losses | 6,663,167.19 | 4,063,029.24 | 64.00% | It was mainly due to the period-on-period decrease in impairment losses on inventories during the reporting period. |
| Gains on disposal of assets | 1,122,671.30 | -310,585.68 | 461.47% | It was due to the period-on-period increase in gains on disposal of non-current assets during the reporting period. |
| Non-operating expenses | 5,895,689.26 | 437,241.73 | 1,248.38% | It was mainly due to the period-on-period increase in the external donation and losses arising from disposal of biological assets during the reporting period. |

II. SHAREHOLDER INFORMATION

(I) Interest of Substantial Shareholders

| Name | Nationality/ Place of registration | Class of Shares | Nature of Interest | Number of Shares | Approximate percentage in the respective class of share capital | Percentage in the total number of Shares |
|--|--|--------------------|--|--|---|---|
| Dr. LOU Boliang ⁽²⁾ | U.S. | A Shares | Interests held jointly with another person; interests of controlled corporation | 323,212,550 | 21.88% | 17.59% |
| Mr. LOU Xiaoqiang ⁽²⁾ | China | A Shares | Beneficial owner; interests held jointly with another person; interests of controlled corporation; interests of spouse | 323,212,550 | 21.88% | 17.59% |
| Ms. ZHENG Bei ⁽²⁾ | China | A Shares | Beneficial owner; Interests held jointly with another person; interests of controlled corporation; interests of spouse | 323,212,550 | 21.88% | 17.59% |
| CITIC Securities Co. Ltd. ⁽³⁾ | China | A Shares | Interest of controlled corporation | 225,313,933 | 15.25% | 12.26% |
| Citigroup Inc. ⁽⁴⁾ | U.S. | H Shares | Interest of controlled corporation | 31,948,880(L) 2,375,300(S) 29,635,025(P) | 8.88% 0.66% 8.23% | 1.74% 0.13% 1.61% |
| Norges Bank | Norway | H Shares | Beneficial owner | 24,944,324(L) | 6.93% | 1.36% |
| JPMorgan Chase & Co. ⁽⁵⁾ | U.S. | H Shares | Interest of controlled corporation | 20,127,813(L) 11,064,208(S) 3,781,733(P) | 5.59% 3.07% 1.05% | 1.10% 0.60% 0.21% |

Notes:

- The letter “L”, “S” and “P” stand for long position, short position and lending pool, respectively.
- As of March 31, 2026, Pharmaron Holdings Limited directly held 180,496,500 A Shares, 76.76% of which is held by Dr. LOU Boliang (both directly and indirectly).

As of March 31, 2026, Mr. LOU Xiaoqiang directly held 60,540,050 A Shares and Ningbo Longtaikang Investment Management Co., Ltd. directly held 40,135,026 A Shares. Ningbo Longtaikang Investment Management Co., Ltd. is wholly-owned by Mr. LOU Xiaoqiang.

As of March 31, 2026, Ms. ZHENG Bei directly held 15,750,000 A Shares and 21,956,986 A Shares directly held by Beihai Duotai Venture Capital Co., Ltd., which is wholly owned by Ms. ZHENG Bei.

As of March 31, 2026, Anyi Longtai Zhongxin Enterprise Management Partnership (Limited Partnership) directly held 4,333,988 A Shares, the general partner of which is Ms. ZHENG Bei.

Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei have entered into a voting rights agreement on October 19, 2018 (which formalizes their pre-existing voting arrangement), pursuant to which they have agreed to reach consensus on any proposal presented to the Board and the general meeting of the shareholders of the Company for voting (the “**Voting Agreement**”). Pursuant to the Voting Agreement, Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei are concert parties and they are deemed to be interested in each other’s interests in our Company under the Securities and Futures Ordinance.

Mr. LOU Xiaoqiang and Ms. ZHENG Bei are spouses.

For the foregoing reasons, as of March 31, 2026, the aggregate interests of Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei in the Company are 323,212,550 A Shares.

3. Shenzhen Xinzhong Kangcheng Investment Partnership (Limited Liability Partnership) (深圳市信中康成投資合夥企業(有限合夥)) (“**Shenzhen Xinzhong Kangcheng**”) and Shenzhen Xinzhong Longcheng Investment Partnership (Limited Liability Partnership) (深圳市信中龍成投資合夥企業(有限合夥)) (“**Shenzhen Xinzhong Longcheng**”) directly held 214,597,333 and 10,716,600 A Shares, respectively. To the best knowledge of our Company, the general partner of Shenzhen Xinzhong Kangcheng and Shenzhen Xinzhong Longcheng is CITIC Buyout Fund Management Company Limited (中信併購基金管理有限公司) (“**CITIC Fund**”). Shenzhen Xinzhong Kangcheng is held as to 50.16% by CITIC Buyout Investment Fund (Shenzhen) (Limited Partnership) (中信併購投資基金(深圳)合夥企業(有限合夥)) (“**CITIC Fund Shenzhen**”) as a limited partner, the general partner of which is CITIC Fund. CITIC Fund is wholly-owned by CITIC Goldstone Investment Co., Ltd (中信金石投資有限公司), which is in turn wholly-owned by CITIC Securities Co. Ltd. (“**CITIC Securities**”), a company listed on the Hong Kong Stock Exchange (stock code: 6030). Shenzhen Xinzhong Longcheng is held as to 72.74% by Anhui Industrial Buyout Fund Partnership (Limited Partnership) (安徽產業併購基金合夥企業(有限合夥)) as a limited partner, the general partner of which is Anhui Xinan Investment Partnership Enterprise (Limited Partnership) (安徽信安投資合夥企業(有限合夥)) (“**Anhui Xin’an**”). The general partner of Anhui Xin’an, being Anhui Xin’an Mergers and Acquisitions Private Fund Management Company (安徽信安併購私募基金管理有限公司), is in turn held as to 80% by CITIC Goldstone Investment Co., Ltd (中信金石投資有限公司).
4. According to the disclosure of interest notice filed by Citigroup Inc. with a relevant event date of March 26, 2026, the following interest in H Shares were held by Citigroup Inc.:

| Name of controlled corporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
|---|---|-----------|-----------------------|------------------------------|
| Citicorp LLC | Citigroup Inc. | 100.00 | N | 29,635,025(L) 0(S) |
| Citibank, N.A. | Citicorp LLC | 100.00 | Y | 29,635,025(L) 0(S) |
| Citigroup Global Markets Holdings Inc. | Citigroup Inc. | 100.00 | N | 2,313,855(L) 2,375,300(S) |
| Citigroup Financial Products Inc. | Citigroup Global Markets Holdings Inc. | 100.00 | N | 2,313,855(L) 2,375,300(S) |
| Citigroup Global Markets Inc. | Citigroup Financial Products Inc. | 100.00 | Y | 0(L) 420,000(S) |
| Citigroup Global Markets Holdings Bahamas Limited | Citigroup Financial Products Inc. | 90.00 | N | 2,313,855(L) 1,955,300(S) |
| Citigroup Global Markets Limited | Citigroup Global Markets Holdings Bahamas Limited | 100.00 | Y | 2,313,855(L) 1,955,300(S) |

The capacity under which the interests are held are as follow:

| Capacity in which interest is held | Number of H Shares |
|---|------------------------------|
| Interest of corporation controlled by you | 2,313,855(L) 2,375,300(S) |
| Approved lending agent | 29,635,025(L) 0(S) |

Additionally, 240,000 H Shares (long position) and 849,600 H Shares (short position) were held through cash settled unlisted derivatives.

5. According to the disclosure of interest notice filed by JPMorgan Chase & Co. with a relevant event date of March 25, 2026, the following interest in H Shares were held by JPMorgan Chase & Co:

| Name of controlled corporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
|---|---|------------------|------------------------------|--------------------------------|
| J.P. Morgan Securities LLC | J.P. Morgan Broker-Dealer Holdings Inc. | 100.00 | Y | 5,943,300(L) 166,000(S) |
| JPMORGAN ASSET MANAGEMENT (UK) LIMITED | JPMORGAN ASSET MANAGEMENT INTERNATIONAL LIMITED | 100.00 | Y | 123,300(L) 0(S) |
| JPMorgan Asset Management (Taiwan) Limited | JPMorgan Asset Management (Asia) Inc. | 100.00 | Y | 52,300(L) 0(S) |
| JPMorgan Chase Bank, National Association | JPMorgan Chase & Co. | 100.00 | Y | 3,781,733(L) 0(S) |
| J.P. MORGAN SECURITIES PLC | J.P. MORGAN CAPITAL HOLDINGS LIMITED | 100.00 | Y | 10,227,180(L) 10,898,208(S) |
| J.P. Morgan Broker-Dealer Holdings Inc. | JPMorgan Chase Holdings LLC | 100.00 | N | 5,943,300(L) 166,000(S) |
| JPMorgan Chase Holdings LLC | JPMorgan Chase & Co. | 100.00 | N | 6,118,900(L) 166,000(S) |
| JPMORGAN ASSET MANAGEMENT INTERNATIONAL LIMITED | JPMorgan Asset Management Holdings Inc. | 100.00 | N | 123,300(L) 0(S) |
| JPMorgan Asset Management Holdings Inc. | JPMorgan Chase Holdings LLC | 100.00 | N | 175,600(L) 0(S) |
| JPMorgan Asset Management (Asia) Inc. | JPMorgan Asset Management Holdings Inc. | 100.00 | N | 52,300(L) 0(S) |
| J.P. MORGAN CAPITAL HOLDINGS LIMITED | J.P. Morgan International Finance Limited | 100.00 | N | 10,227,180(L) 10,898,208(S) |
| J.P. Morgan International Finance Limited | JPMorgan Chase Bank, National Association | 100.00 | N | 10,227,180(L) 10,898,208(S) |
| JPMorgan Chase Bank, National Association | JPMorgan Chase & Co. | 100.00 | N | 10,227,180(L) 10,898,208(S) |

The capacity under which the interests are held are as follow:

| Capacity in which interest is held | Number of H Shares |
|---|--------------------------------|
| Beneficial owner | 10,393,180(L) 11,064,208(S) |
| Investment manager | 175,600(L) 0(S) |
| Person having a security interest in shares | 5,777,300(L) 0(S) |
| Approved lending agent | 3,781,733(L) 0(S) |

Additionally, 1,036,763 H Shares (long position) and 2,017,525 H shares (short position) were held through physically settled unlisted derivatives. 395,300 H Shares (long position) and 6,324,075 H Shares (short position) were held through cash settled unlisted derivatives.

6. As of March 31, 2026, the total number of issued A Shares and H Shares were 1,477,305,741 and 359,977,887, respectively.

(II) Total number of preferred shareholders and the shareholdings of top 10 preferred shareholders

Applicable Not Applicable

(III) Change in shares subject to trading restrictions

Applicable Not Applicable

Unit: share

| Name of shareholders | Period beginning shares subject to trading restrictions | Number of shares released from trading restrictions during the reporting period | Increase in shares subject to trading restrictions during the reporting period | Period-end shares subject to trading restrictions | Reason for trading restrictions | Proposed date of release from trading restrictions |
|----------------------------|---|---|--|---|--|---|
| Mr. LOU Xiaoqiang (樓小強) | 45,405,037 | 0 | 0 | 45,405,037 | Locked shares held by the director/senior management | The locked shares held by the director/senior management is released from trading restrictions in accordance with relevant laws and regulations |
| Ms. ZHENG Bei (鄭北) | 11,812,500 | 0 | 0 | 11,812,500 | Locked shares held by the director/senior management | The locked shares held by the director/senior management is released from trading restrictions in accordance with relevant laws and regulations |
| Ms. Li Lihua (李麗華) | 56,250 | 0 | 0 | 56,250 | Locked shares held by the director/senior management | The locked shares held by the director/senior management is released from trading restrictions in accordance with relevant laws and regulations |
| Total | <u>57,273,787</u> | <u>0</u> | <u>0</u> | <u>57,273,787</u> | | |

III. OTHER SIGNIFICANT EVENTS

✓ Applicable □ Not Applicable

(I) Equity Restructuring of Aistarfish Technology and Kangsida

In February 2026, the Company completed the internal equity restructuring of Aistarfish Technology Co., Ltd. (“**Aistarfish Technology**”) and Beijing Kangsida Health Management Co., Ltd. (“**Kangsida**”). The Company directly held 70.44% of the equity interest in Aistarfish Technology, which in turn directly held 100% of the equity interest in Kangsida. The above-mentioned equity restructuring is conducive to further streamlining the Company’s business segments, optimising its equity structure and enhancing R&D efficiency and service quality.

(II) Summary of Other Significant Events during the Reporting Period

| Description | Date of disclosure of interim announcements | Search index on the website disclosing the interim announcements |
|---|---|---|
| Capital increase in Ningbo Yongxin Kangjun Venture Capital Partnership (Limited Partnership) | January 9, 2026 | Announcement Regarding Additional Subscription for Interests in Investment Funds, disclosure website: https://www1.hkexnews.hk |
| Completion of additional capital contribution to PharmaGend Global Medical Services Pte. Ltd. | January 9, 2026 | Announcement Regarding Progress in Respect of Additional Investment in Overseas Investee Company and Related Transaction, disclosure website: https://www1.hkexnews.hk |
| Placing of New H Shares Under General Issuance Mandate | January 15, 2026 and January 22, 2026 | Placing of New H Shares Under General Issuance Mandate, Completion of Placing of New H Shares Under General Issuance Mandate, disclosure website: https://www1.hkexnews.hk |
| 2025 Profit Distribution Plan | March 30, 2026 | Final Dividend in Cash for the year ended December 31, 2025, disclosure website: https://www1.hkexnews.hk |
| Increase in Registered Capital and Amendment to the Articles of Association | March 30, 2026 | Proposed Increase in Registered Capital and Proposed Amendments to the Articles of Association, disclosure website: https://www1.hkexnews.hk |
| Adoption of New Corporate Governance Policies | March 30, 2026 | Overseas Regulatory Announcement: Compensation Management Policy for Directors and Senior Management, https://www1.hkexnews.hk |

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Financial Statements

1. Consolidated Balance Sheet

Prepared by: Pharmaron Beijing Co., Ltd.
March 31, 2026

| | <i>Unit: RMB</i> | |
|---|--|--|
| Item | Balance at the end of the period | Balance at the beginning of the period |
| Current assets: | | |
| Cash and bank balances | 2,378,989,128.19 | 1,017,482,059.69 |
| Deposit reservation for balance | | |
| Lending to banks and other financial institutions | | |
| Held-for-trading financial assets | 597,948,572.40 | 714,072,862.78 |
| Derivative financial assets | 1,547,675.85 | 22,549,918.77 |
| Note receivables | 10,853,880.73 | 14,807,296.43 |
| Trade receivables | 2,660,923,269.99 | 2,707,105,477.69 |
| Trade receivables financing | | |
| Prepayments | 101,933,567.76 | 18,917,151.23 |
| Premium receivables | | |
| Reinsurance account receivables | | |
| Reinsurance deposit receivables | | |
| Other receivables | 96,906,217.82 | 85,964,218.25 |
| Including: Interest receivables | | |
| Dividend receivables | | |
| Financial assets held under repurchase agreements | | |
| Inventories | 1,693,670,515.27 | 1,472,304,694.15 |
| Including: Data resources | | |
| Contract assets | 496,825,743.38 | 465,831,584.75 |
| Assets held for sale | | |
| Non-current assets due within one year | | |
| Other current assets | 1,010,966,431.65 | 1,259,131,000.27 |
| Total current assets | 9,050,565,003.04 | 7,778,166,264.01 |

| Item | Balance at the end of the period | Balance at the beginning of the period |
|---|---|---|
| Non-current assets: | | |
| Disbursement of loans and advances | | |
| Debt investments | | |
| Other debt investments | | |
| Long-term receivables | | |
| Long-term equity investments | 646,001,320.85 | 639,860,751.84 |
| Other investments in equity instruments | | |
| Other non-current financial assets | 572,139,616.16 | 518,451,308.32 |
| Investment properties | | |
| Fixed assets | 9,173,811,004.29 | 8,932,840,401.08 |
| Construction in progress | 2,309,258,562.83 | 2,365,410,094.23 |
| Productive biological assets | 177,902,549.99 | 172,574,104.23 |
| Oil & gas assets | | |
| Right-of-use assets | 533,491,891.74 | 498,873,801.42 |
| Intangible assets | 1,168,399,217.57 | 1,196,614,017.81 |
| Including: Data resources | | |
| Development expenses | | |
| Including: Data resources | | |
| Goodwill | 3,535,087,310.02 | 3,585,973,613.61 |
| Long-term deferred expenses | 590,896,473.42 | 617,985,097.03 |
| Deferred tax assets | 289,630,043.31 | 262,906,689.73 |
| Other non-current assets | 514,522,828.49 | 524,126,435.73 |
| Total non-current assets | <u>19,511,140,818.67</u> | <u>19,315,616,315.03</u> |
| Total assets | <u>28,561,705,821.71</u> | <u>27,093,782,579.04</u> |

| Item | Balance at the end of the period | Balance at the beginning of the period |
|--|--|--|
| Current liabilities: | | |
| Short-term borrowings | 1,196,780,464.58 | 1,265,397,031.24 |
| Borrowings from the Central Bank | | |
| Borrowings from banks and other financial institutions | | |
| Held-for-trading financial liabilities | | |
| Derivative financial liabilities | 5,643,596.52 | |
| Note payables | | |
| Trade payables | 628,247,829.66 | 606,589,731.73 |
| Advances from customers | | |
| Contract liabilities | 1,003,737,259.79 | 960,613,392.46 |
| Financial assets sold for repurchase | | |
| Customer and inter-bank deposits | | |
| Deposit for securities trading brokerage | | |
| Deposit for securities underwriting brokerage | | |
| Employee benefits payables | 948,034,906.75 | 874,330,149.82 |
| Tax payables | 242,362,346.00 | 207,183,976.81 |
| Other payables | 656,648,328.89 | 802,462,670.16 |
| Including: Interests payables | | |
| Dividend payables | | 9,998,000.00 |
| Fees and commissions payables | | |
| Reinsurance account payables | | |
| Liabilities held for sale | | |
| Non-current liabilities due within one year | 3,664,014,697.58 | 3,623,789,203.03 |
| Other current liabilities | 24,896,966.74 | 23,636,817.38 |
| Total current liabilities | 8,370,366,396.51 | 8,364,002,972.63 |
| Non-current liabilities: | | |
| Insurance contract reserves | | |
| Long-term borrowings | 1,843,721,417.59 | 1,771,805,796.68 |
| Bond payables | | |
| Including: Preferred shares | | |
| Perpetual bonds | | |
| Lease liabilities | 396,303,792.92 | 379,422,832.85 |
| Long-term payables | | |
| Long-term employee benefits payables | | |
| Provisions | | |
| Deferred income | 434,934,092.50 | 442,864,645.23 |
| Deferred tax liabilities | 401,747,612.31 | 397,151,436.44 |
| Other non-current liabilities | | |
| Total non-current liabilities | 3,076,706,915.32 | 2,991,244,711.20 |
| Total liabilities | 11,447,073,311.83 | 11,355,247,683.83 |

| Item | Balance at the end of the period | Balance at the beginning of the period |
|--|---|--|
| Equity: | | |
| Share capital | 1,837,283,628.00 | 1,778,842,866.00 |
| Other equity instruments | | |
| Including: Preferred shares | | |
| Perpetual bonds | | |
| Capital reserve | 6,078,642,139.52 | 4,950,230,362.86 |
| Less: Treasury shares | 304,891,961.34 | 304,891,961.34 |
| Other comprehensive income | -56,096,680.68 | 71,798,265.22 |
| Specific reserve | | |
| Surplus reserve | 889,421,433.00 | 889,421,433.00 |
| General risk provision | | |
| Retained earnings | 8,014,117,525.28 | 7,678,758,290.34 |
| Total equity attributable to the owners of the parent | 16,458,476,083.78 | 15,064,159,256.08 |
| Non-controlling interests | 656,156,426.10 | 674,375,639.13 |
| | <u>17,114,632,509.88</u> | <u>15,738,534,895.21</u> |
| Total equity | 17,114,632,509.88 | 15,738,534,895.21 |
| | <u>28,561,705,821.71</u> | <u>27,093,782,579.04</u> |
| Total liabilities and equity | 28,561,705,821.71 | 27,093,782,579.04 |

Legal representative:
LOU Boliang

Chief Financial Officer:
LI Shing Chung Gilbert

Person in charge of
Accounting Department:
LI Shing Chung Gilbert

2. Consolidated Income Statement

Unit: RMB

| Item | Amount of the current period | Amount of the previous period |
|---|---------------------------------|----------------------------------|
| 1. Total revenue | 3,578,424,402.86 | 3,098,813,569.89 |
| Including: Revenue | 3,578,424,402.86 | 3,098,813,569.89 |
| Interest income | | |
| Insurance premium earned | | |
| Fee and commission income | | |
| 2. Total cost | 3,191,949,805.22 | 2,713,717,115.43 |
| Including: Cost | 2,415,585,477.35 | 2,055,900,744.63 |
| Interest expenses | | |
| Fee and commission expenses | | |
| Surrender value | | |
| Net claim paid | | |
| Net change in insurance contract reserves | | |
| Insurance policy dividend paid | | |
| Reinsurance expenses | | |
| Taxes and surcharges | 29,748,318.65 | 23,236,218.65 |
| Selling expenses | 78,072,061.23 | 68,847,642.64 |
| Administrative expenses | 442,043,611.10 | 396,944,216.69 |
| Research and development costs | 139,766,368.51 | 122,210,590.15 |
| Finance expenses | 86,733,968.38 | 46,577,702.67 |
| Including: Interest expenses | 51,563,793.25 | 43,875,941.36 |
| Interest income | 13,514,894.90 | 6,725,935.54 |
| Add: Other income | 22,699,704.16 | 13,846,641.70 |
| Investment income (“-” indicating loss) | 21,246,202.92 | -14,632,689.59 |
| Including: Income from investments in associates and joint ventures | 14,215,653.09 | -22,797,249.91 |
| Gains on derecognition of financial assets measured at amortized cost | | |
| Foreign exchange gains (“-” indicating loss) | | |
| Net gain on exposure hedging (“-” indicating loss) | | |
| Gains on change in fair value (“-” indicating loss) | -8,181,579.08 | -12,799,396.87 |
| Credit impairment losses (“-” indicating loss) | -11,514,696.76 | -11,390,647.31 |
| Assets impairment losses (“-” indicating loss) | 6,663,167.19 | 4,063,029.24 |
| Gains on disposal of assets (“-” indicating loss) | 1,122,671.30 | -310,585.68 |
| 3. Operating profit (“-” indicating loss) | 418,510,067.37 | 363,872,805.95 |
| Add: Non-operating income | 144,856.79 | 151,206.71 |
| Less: Non-operating expenses | 5,895,689.26 | 437,241.73 |
| 4. Profit before tax (“-” indicating total loss) | 412,759,234.90 | 363,586,770.93 |
| Less: Income tax expenses | 102,349,213.55 | 83,932,205.84 |

| Item | Amount of the current period | Amount of the previous period |
|---|---------------------------------|----------------------------------|
| 5. Net profit (“-” indicating net loss) | 310,410,021.35 | 279,654,565.09 |
| (i) By continuity of operations | | |
| 1. Net profit from continuing operations (“-” indicating net loss) | 310,410,021.35 | 279,654,565.09 |
| 2. Net profit from discontinued operations (“-” indicating net loss) | | |
| (ii) By ownership | | |
| 1. Net profit attributable to owners of the parent (“-” indicating net loss) | 335,359,234.94 | 305,575,186.04 |
| 2. Net profit attributable to non-controlling interests (“-” indicating net loss) | -24,949,213.59 | -25,920,620.95 |
| 6. Other comprehensive income, net of tax | -134,821,431.62 | 110,016,172.44 |
| Other comprehensive income attributable to owners of the parent, net of tax | -127,894,945.90 | 106,303,613.01 |
| (i) Other comprehensive income that may not be reclassified to profit or loss | | |
| 1. Changes arising from remeasurement under defined benefit plan | | |
| 2. Other comprehensive income that may not be transferred to gain or loss under equity method | | |
| 3. Change in fair value of investments in other equity instruments | | |
| 4. Change in fair value of own credit risk | | |
| 5. Others | | |
| (ii) Other comprehensive income that will be reclassified to profit or loss | -127,894,945.90 | 106,303,613.01 |
| 1. Other comprehensive income that may be reclassified to profit or loss under equity method | -22,439.58 | |
| 2. Change in fair value of other debt investments | | |
| 3. Amount included in other comprehensive income on reclassification of financial assets | | |
| 4. Credit impairment allowance of other debt investments | | |
| 5. Cash flow hedging reserve | -4,746,033.48 | 17,933,397.06 |
| 6. Exchange difference on translation of foreign financial statements | -123,126,472.84 | 88,370,215.95 |
| 7. Others | | |
| Other comprehensive income attributable to the non-controlling interests, net of tax | -6,926,485.72 | 3,712,559.43 |
| 7. Total comprehensive income | 175,588,589.73 | 389,670,737.53 |
| (i) Total comprehensive income attributable to owners of the parent | 207,464,289.04 | 411,878,799.05 |
| (ii) Total comprehensive income attributable to the non-controlling interests | -31,875,699.31 | -22,208,061.52 |
| 8. Earnings per share: | | |
| (i) Basic earnings per share | 0.1860 | 0.1736 |
| (ii) Diluted earnings per share | 0.1850 | 0.1733 |

Legal representative:
LOU Boliang

Chief Financial Officer:
LI Shing Chung Gilbert

Person in charge of
Accounting Department:
LI Shing Chung Gilbert

3. Consolidated Statement of Cash Flows

| Item | <i>Unit: RMB</i> | |
|---|---------------------------------|----------------------------------|
| | Amount of the current period | Amount of the previous period |
| 1. Cash flows from operating activities: | | |
| Cash received from sales of goods and rendering of services | 3,687,917,362.08 | 3,202,713,168.46 |
| Net increase in customers deposits, due to banks and other financial institutions | | |
| Net increase in placements from the Central Bank | | |
| Net increase in placements from other financial institutions | | |
| Cash received from premiums of original insurance contracts | | |
| Net cash received from reinsurance business | | |
| Net increase in deposit from policyholders and investment | | |
| Cash received from interests, fees and commissions | | |
| Net increase in placements from banks and other financial institutions | | |
| Net increase in repurchase agreements | | |
| Net cash received from securities trading brokerage | | |
| Refunds of taxes and surcharges | 151,050,511.32 | 226,032,233.02 |
| Other cash received relating to operating activities | 30,251,064.81 | 43,304,230.44 |
| | <hr/> | <hr/> |
| Subtotal of cash inflow from operating activities | 3,869,218,938.21 | 3,472,049,631.92 |
| | <hr/> | <hr/> |
| Cash paid for goods and services | 985,871,494.18 | 611,393,811.71 |
| Net increase in loans and advances to customers | | |
| Net increase in deposits with the Central Bank and other financial institutions | | |
| Cash paid for compensation pay-outs of original insurance contracts | | |
| Net increase in placements with banks and other financial institutions | | |
| Cash paid for interest, fees and commissions | | |
| Cash paid for insurance dividends | | |
| Cash paid to and on behalf of employees | 1,580,491,976.36 | 1,398,959,106.45 |
| Cash paid for taxes and surcharges | 135,583,571.55 | 146,967,843.36 |
| Other cash paid relating to operating activities | 562,831,979.57 | 461,899,726.13 |
| | <hr/> | <hr/> |
| Subtotal of cash outflow from operating activities | 3,264,779,021.66 | 2,619,220,487.65 |
| | <hr/> | <hr/> |
| Net cash flow from operating activities | 604,439,916.55 | 852,829,144.27 |
| | <hr/> <hr/> | <hr/> <hr/> |

| Item | Amount of the current period | Amount of the previous period |
|---|---------------------------------|----------------------------------|
| 2. Cash flow from investing activities: | | |
| Cash received from disposal of investments | 2,863,658,512.68 | 956,984,115.70 |
| Cash received from return on investments | 12,268,932.57 | 6,676,414.98 |
| Net cash received from disposal of fixed assets, intangible assets and other long-term assets | 571,594.64 | 175,381.84 |
| Net cash received from disposal of subsidiaries and other business entities | | |
| Other cash received relating to investing activities | 4,240,392.28 | 5,790,000.00 |
| Subtotal of cash inflows from investing activities | <u>2,880,739,432.17</u> | <u>969,625,912.52</u> |
| Cash paid to acquire fixed assets, intangible assets and other long-term assets | 579,140,750.70 | 555,720,062.54 |
| Cash paid to acquire investments | 2,525,096,643.41 | 1,471,014,444.45 |
| Net increase in pledged loans | | |
| Net cash paid to acquire subsidiaries and other business entities | 19,173,084.76 | 150,753,281.16 |
| Other cash paid relating to investing activities | | 4,233,362.89 |
| Subtotal of cash outflows from investing activities | <u>3,123,410,478.87</u> | <u>2,181,721,151.04</u> |
| Net cash flow from investing activities | <u>-242,671,046.70</u> | <u>-1,212,095,238.52</u> |
| 3. Cash flow from financing activities: | | |
| Cash received from capital contributions | 1,185,807,276.78 | |
| Including: Cash received from capital contributions by non-controlling shareholders of subsidiaries | | |
| Cash received from borrowings | 318,864,183.29 | 148,201,518.67 |
| Other cash received relating to financing activities | | |
| Subtotal of cash inflows from financing activities | <u>1,504,671,460.07</u> | <u>148,201,518.67</u> |
| Cash paid for repayments of borrowings | 302,346,000.00 | 139,035,205.19 |
| Cash payment for distribution of dividends, profits or interest expenses | 56,983,731.93 | 40,651,616.90 |
| Including: Dividends and profit paid by subsidiaries to non-controlling shareholders | 9,998,000.00 | |
| Other cash paid relating to financing activities | 39,678,994.65 | 67,441,412.50 |
| Subtotal of cash outflow from financing activities | <u>399,008,726.58</u> | <u>247,128,234.59</u> |
| Net cash flows from financing activities | <u>1,105,662,733.49</u> | <u>-98,926,715.92</u> |

| Item | Amount of the current period | Amount of the previous period |
|---|---------------------------------|----------------------------------|
| 4. Effect of foreign exchange rate changes on cash and cash equivalents | <u>-22,987,586.46</u> | <u>8,810,240.18</u> |
| 5. Net increase in cash and cash equivalents | 1,444,444,016.88 | -449,382,569.99 |
| Add: Period-beginning balance of cash and cash equivalents | <u>842,689,715.42</u> | <u>1,622,961,833.68</u> |
| 6. Period-end balance of cash and cash equivalents | <u><u>2,287,133,732.30</u></u> | <u><u>1,173,579,263.69</u></u> |

(II) Adjustment of relevant items in the financial statements at the beginning of the year of first implementation of the new accounting standards starting from 2026

Applicable Not Applicable

(III) Audit Report

Whether the First Quarterly Report has been audited

Yes No

The First Quarterly Report of the Company has not been audited.

(IV) Quarterly Condensed Consolidated Financial Statements Prepared in Accordance with IFRSs

1. Consolidated Statement of Profit or Loss¹

For the three months ended March 31, 2026

| | Three months ended March 31, | |
|---|-------------------------------------|--------------------|
| | 2026 | 2025 |
| | RMB'000 | RMB'000 |
| REVENUE | 3,578,424 | 3,098,814 |
| Cost of sales | <u>(2,412,343)</u> | <u>(2,054,226)</u> |
| Gross profit | 1,166,081 | 1,044,588 |
| Other income and gains | 41,095 | 26,764 |
| Other expenses | (58,424) | (19,358) |
| Selling and distribution expenses | (78,072) | (68,848) |
| Administrative expenses | (468,857) | (418,354) |
| Research and development costs | (139,766) | (122,211) |
| Impairment losses on financial and contract assets, net of reversal | (11,950) | (12,321) |
| Finance costs | (51,564) | (43,876) |
| Share of gains/(losses) of associates | <u>14,216</u> | <u>(22,797)</u> |
| Profit before tax | 412,759 | 363,587 |
| Income tax expense | <u>(102,349)</u> | <u>(83,932)</u> |
| Profit for the period | <u>310,410</u> | <u>279,655</u> |
| Attributable to: | | |
| Owners of the parent | 335,359 | 305,575 |
| Non-controlling interests | <u>(24,949)</u> | <u>(25,920)</u> |
| | <u>310,410</u> | <u>279,655</u> |
| EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT | RMB | RMB |
| Basic | | |
| For profit for the period | <u>0.1860</u> | <u>0.1736</u> |
| Diluted | | |
| For profit for the period | <u>0.1850</u> | <u>0.1733</u> |

¹ Any discrepancies in data below between the total shown and the sum of the amounts listed are due to rounding.

2. Consolidated Statement of Financial Position²

March 31, 2026

| | March 31, 2026 RMB'000 | December 31, 2025 RMB'000 |
|---|---------------------------------------|---------------------------------|
| NON-CURRENT ASSETS | | |
| Property, plant and equipment | 12,276,369 | 12,124,897 |
| Right-of-use assets | 884,666 | 852,287 |
| Goodwill | 3,535,087 | 3,585,974 |
| Other intangible assets | 614,822 | 634,539 |
| Investments in associates | 646,001 | 639,861 |
| Equity investments at fair value through profit or loss | 572,140 | 518,451 |
| Biological assets | 177,903 | 172,574 |
| Deferred tax assets | 289,630 | 262,907 |
| Other non-current assets | 514,523 | 524,126 |
| | <hr/> | <hr/> |
| Total non-current assets | 19,511,141 | 19,315,616 |
| CURRENT ASSETS | | |
| Inventories | 766,986 | 641,158 |
| Contract costs | 508,726 | 422,816 |
| Trade and bills receivable | 2,671,777 | 2,721,913 |
| Contract assets | 496,826 | 465,832 |
| Biological assets | 417,958 | 408,331 |
| Prepayments, other receivables and other assets | 1,209,806 | 1,364,012 |
| Financial assets at fair value through profit or loss | 597,949 | 714,073 |
| Derivative financial instruments | 1,548 | 22,550 |
| Pledged deposits | 90,930 | 174,792 |
| Cash and cash equivalents | 2,288,059 | 842,690 |
| | <hr/> | <hr/> |
| Total current assets | 9,050,565 | 7,778,167 |

| | March 31, 2026 RMB'000 | December 31, 2025 RMB'000 |
|--|---------------------------------------|---------------------------------|
| CURRENT LIABILITIES | | |
| Interest-bearing bank borrowings | 4,714,229 | 4,766,489 |
| Trade payables | 628,248 | 606,590 |
| Other payables and accruals | 1,686,644 | 1,774,415 |
| Contract liabilities | 1,003,737 | 960,613 |
| Lease liabilities | 146,566 | 122,698 |
| Derivative financial instruments | 5,644 | – |
| Tax payable | 185,299 | 133,198 |
| | <hr/> | <hr/> |
| Total current liabilities | 8,370,367 | 8,364,003 |
| | <hr/> | <hr/> |
| NET CURRENT ASSETS | 680,198 | (585,836) |
| | <hr/> | <hr/> |
| TOTAL ASSETS LESS CURRENT LIABILITIES | 20,191,339 | 18,729,780 |
| | <hr/> <hr/> | <hr/> <hr/> |
| NON-CURRENT LIABILITIES | | |
| Interest-bearing bank borrowings | 1,843,721 | 1,771,806 |
| Deferred tax liabilities | 401,748 | 397,151 |
| Deferred income | 434,934 | 442,865 |
| Lease liabilities | 396,304 | 379,423 |
| | <hr/> | <hr/> |
| Total non-current liabilities | 3,076,707 | 2,991,245 |
| | <hr/> | <hr/> |
| NET ASSETS | 17,114,632 | 15,738,535 |
| | <hr/> <hr/> | <hr/> <hr/> |
| EQUITY | | |
| Share capital | 1,837,284 | 1,778,843 |
| Treasury shares | (304,892) | (304,892) |
| Reserves | 14,926,084 | 13,590,208 |
| | <hr/> | <hr/> |
| Equity attributable to owners of the parent | 16,458,476 | 15,064,159 |
| | <hr/> | <hr/> |
| Non-controlling interests | 656,156 | 674,376 |
| | <hr/> | <hr/> |
| Total equity | 17,114,632 | 15,738,535 |
| | <hr/> <hr/> | <hr/> <hr/> |

² Any discrepancies in data below between the total shown and the sum of the amounts listed are due to rounding.

3. *Non-IFRSs adjusted net profit for the period attributable to owners of the parent*

To supplement the financial statements prepared by us, we use non-IFRSs adjusted net profit attributable to owners of the parent as an additional financial measure. We define non-IFRSs adjusted net profit attributable to owners of the parent as net profit before certain expenses/ (gains) as set out in the table below.

The Company believes that the consideration of the non-IFRSs adjusted net profit attributable to owners of the parent by eliminating the impact of certain incidental, non-cash or non-operating items is useful for better understanding and assessing underlying business performance and operating trends for the Company's management, shareholders and potential investors.

The non-IFRSs adjusted net profit attributable to owners of the parent is not an alternative to (i) profit before tax or net profit (as determined in accordance with IFRSs) as a measure of our operating performance, (ii) cash flows from operating, investing and financing activities as a measure of our ability to satisfy our cash needs, or (iii) any other measures of performance or liquidity. In addition, the presentation of the non-IFRSs adjusted net profit attributable to owners of the parent is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRSs. Shareholders and potential investors should not view the non-IFRSs adjusted net profit attributable to owners of the parent on a stand-alone basis or as a substitute for results under the IFRSs, or as being comparable to results reported or forecasted by other companies.

| | Three months ended March 31, | |
|--|-------------------------------------|----------------|
| | 2026 | 2025 |
| | RMB'000 | RMB'000 |
| Profit attributable to owners of the parent | 335,359 | 305,575 |
| Add: | | |
| Share-based compensation expenses | 16,220 | 16,331 |
| Foreign exchange related losses | 41,432 | 1,676 |
| Realized and unrealized losses from equity investments | 6,128 | 25,693 |
| Amortization of intangible assets from acquisitions | 7,071 | 166 |
| Non-IFRS adjusted net profit attributable to owners of the parent | 406,210 | 349,441 |

In the first quarter of 2026, non-IFRS adjusted net profit attributable to owners of the parent increased by 16.2% as compared with the corresponding period of the previous year.